Generic GUANETHIDINE MONOSULFATE; HYDROCHLOROTHIAZIDE INN equivalents, pharmaceutical patent and freedom to operate

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	ESIMIL	guanethidine monosulfate; hydrochlorothiazide	TABLET;ORAL	013553-001	Approved Prior to Jan 1, 1982		DISCN	No	No	⤷ Start Trial	⤷ Start Trial				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Last updated: September 3, 2026

Guanethidine monosulfate is a commercially obsolete antihypertensive with no meaningful current branded market in the United States. Hydrochlorothiazide remains a widely used, low-cost generic diuretic, primarily in fixed-dose combinations with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, and other antihypertensive agents. The combined commercial opportunity for guanethidine monosulfate and hydrochlorothiazide is therefore historical rather than growth-oriented.

Guanethidine has limited or absent current commercial supply in major regulated markets. Hydrochlorothiazide has durable prescription volume but weak pricing power, limited patent protection, and intense generic competition. No active biosimilar issue applies to either product.

What are guanethidine monosulfate and hydrochlorothiazide used for?

Guanethidine monosulfate is a peripheral adrenergic neuron-blocking agent that reduces sympathetic nervous system activity and lowers blood pressure. Its historical use was treatment of moderate-to-severe hypertension.

Hydrochlorothiazide is a thiazide diuretic that reduces sodium and water reabsorption in the distal renal tubule. It is used for hypertension and edema and is frequently prescribed as part of combination antihypertensive therapy.

Attribute	Guanethidine monosulfate	Hydrochlorothiazide
Drug class	Adrenergic neuron blocker	Thiazide diuretic
Primary historical/current use	Hypertension; largely obsolete	Hypertension and edema
Regulatory status	Historical prescription product; limited current availability	Approved and widely marketed as a generic
Commercial form	Tablets; historical products and combinations	Tablets, capsules, and fixed-dose combinations
Current competitive position	Replaced by newer antihypertensives	Commodity generic with persistent demand
Biosimilar exposure	None	None
Patent relevance	Historical patents expired	Core patents expired; combination patents vary by product

What is the current market status of guanethidine monosulfate?

Guanethidine monosulfate has effectively exited mainstream pharmaceutical markets. The drug was displaced by beta blockers, thiazide diuretics, calcium-channel blockers, ACE inhibitors, angiotensin receptor blockers, and later antihypertensive combinations.

Its adverse-effect profile contributed to the decline. Guanethidine can cause orthostatic hypotension, diarrhea, nasal congestion, sexual dysfunction, and impaired ability to increase heart rate during exertion. These limitations reduced its use compared with drugs that offered more flexible dosing and better tolerability.

The current market has four defining characteristics:

Limited or discontinued commercial supply in major markets.
No meaningful branded promotion.
Minimal new clinical development.
Demand concentrated in historical-use, specialist, or exceptional-access settings, if available at all.

The former brand Ismelin is associated with guanethidine sulfate. Historical FDA records identify guanethidine sulfate as an approved antihypertensive product, but the product does not have the commercial position of an actively marketed branded drug today.[1][2]

Does guanethidine monosulfate have current U.S. market revenue?

No reliable public source reports material current U.S. revenue for guanethidine monosulfate. The product is not a significant commercial contributor to the antihypertensive market, and any remaining sales would likely be small, irregular, or tied to limited-supply channels.

Public company filings generally do not disclose guanethidine revenue separately. If sold by a niche supplier, revenue would normally be embedded in a broader generic or specialty portfolio.

What is the market trajectory for hydrochlorothiazide?

Hydrochlorothiazide has a different financial trajectory. It is a mature, high-volume generic ingredient with low average selling prices and substantial substitution pressure.

The drug remains relevant because:

Hypertension is a chronic, high-prevalence condition.
Thiazide diuretics remain guideline-supported treatment options.
Hydrochlorothiazide is familiar to prescribers and pharmacies.
The ingredient is available in numerous fixed-dose combinations.
Generic manufacturing is established across multiple regions.

Its commercial value is driven by volume, supply reliability, and combination-product participation rather than exclusivity or premium pricing.

Why does hydrochlorothiazide continue to sell after patent expiry?

Hydrochlorothiazide retains demand because clinical utilization persists after loss of exclusivity. Patent expiry removes pricing protection but does not eliminate the underlying therapeutic need.

The commercial model is typically based on:

Large prescription volume.
Low-cost tablets.
Formulary inclusion.
Pharmacy substitution.
Combination products such as lisinopril/hydrochlorothiazide, losartan/hydrochlorothiazide, valsartan/hydrochlorothiazide, and irbesartan/hydrochlorothiazide.

Manufacturers compete on manufacturing cost, regulatory compliance, supply continuity, and procurement contracts. The market is vulnerable to price erosion when several suppliers compete, but shortages or manufacturing exits can temporarily improve pricing.

What patents protect guanethidine monosulfate and hydrochlorothiazide?

The core composition-of-matter protection for both active ingredients expired many years ago. Neither ingredient has a commercially meaningful remaining U.S. composition patent estate.

Patent category	Guanethidine monosulfate	Hydrochlorothiazide
Core compound patent	Expired	Expired
Basic tablet formulation	Expired or commercially irrelevant	Expired or commercially irrelevant
Method-of-use patents	No material current exclusivity identified	No material current exclusivity for conventional hypertension use
Fixed-dose combination patents	Historical and generally expired	Some product-specific formulation or combination patents may exist, but the API itself is unprotected
Pediatric exclusivity	No current commercial significance	Product-specific, not an API-wide protection
Regulatory exclusivity	None of material current value	None for the mature generic API

The FDA Orange Book remains the principal U.S. reference for listed patents and regulatory exclusivity associated with approved prescription products.[3] For hydrochlorothiazide, any current patent issue generally relates to a particular combination, dosage form, release profile, or branded product rather than the basic molecule.

Are there formulation patents for hydrochlorothiazide combinations?

Some branded antihypertensive combinations may have had patents covering formulation, manufacturing, dosage design, or a combination of active ingredients. Those patents do not create broad exclusivity over hydrochlorothiazide.

A generic manufacturer must assess:

Whether the target product is listed in the Orange Book.
Whether listed patents remain unexpired.
Whether the generic applicant will certify under Paragraph IV.
Whether the product has a different dosage form or release profile.
Whether the combination claim covers the proposed product.

For immediate-release hydrochlorothiazide tablets, the patent barrier is generally weak. For branded fixed-dose combinations, product-specific analysis remains necessary.

When did guanethidine and hydrochlorothiazide lose exclusivity?

Both drugs lost meaningful exclusivity decades ago. Exact patent expiry dates depend on the original patent family, jurisdiction, patent-term adjustments, and product-specific claims. The commercial conclusion is clear: neither active ingredient has a current U.S. composition patent that supports premium pricing.

U.S. exclusivity timeline

Period	Guanethidine monosulfate	Hydrochlorothiazide
Initial commercialization	Mid-20th-century antihypertensive use	Mid-20th-century diuretic use
Branded market phase	Historical Ismelin and related products	Historical branded products, including Esidrix and combinations
Generic competition	Long established	Long established
Current exclusivity	None of material commercial value	None for the standalone API
Current market status	Obsolete or limited supply	Active commodity generic

The absence of current exclusivity means that commercial performance is determined by demand, manufacturing economics, procurement, and supply-chain conditions rather than patent strategy.

What is the Orange Book status of guanethidine monosulfate and hydrochlorothiazide?

The Orange Book does not create market exclusivity. It records approved drug products, therapeutic equivalence information, and applicable listed patents and exclusivity data.

For guanethidine monosulfate, the key issue is product availability and marketing status rather than patent protection. A historical approval does not establish that a product is currently marketed.

For hydrochlorothiazide, the Orange Book contains numerous approved products and combination products. Standalone generic hydrochlorothiazide is generally therapeutically substitutable when the strength, dosage form, and product requirements match the reference product.[3]

Marketing status should be checked against FDA discontinued-drug records and current labeling databases. DailyMed provides current or historical labeling submitted by manufacturers but does not guarantee continuous commercial availability.[4]

Are there Paragraph IV challenges involving these drugs?

Paragraph IV litigation is unlikely to create material commercial risk for standalone guanethidine monosulfate or conventional hydrochlorothiazide tablets because the relevant patents have largely expired or have limited economic significance.

Paragraph IV exposure may arise for:

A newly developed hydrochlorothiazide combination.
A modified-release formulation.
A branded product with unexpired formulation claims.
A 505(b)(2) product relying on a listed reference drug.
A combination product with device, dosing, or manufacturing claims.

For a conventional generic hydrochlorothiazide tablet, the primary risk is not patent litigation. It is price compression, procurement loss, manufacturing compliance, and supply interruption.

Which companies compete in the hydrochlorothiazide market?

Hydrochlorothiazide is supplied by a broad field of generic manufacturers and contract manufacturers. Market participation varies by country and by product strength.

Relevant competitive groups include:

Large generic companies with broad antihypertensive portfolios.
Regional manufacturers serving government and hospital tenders.
Contract manufacturers supplying private-label products.
Branded companies selling fixed-dose combinations.
Specialty suppliers maintaining low-volume or legacy products.

The competitive landscape is fragmented. No single company can generally control the standalone hydrochlorothiazide market through intellectual property. Competitive advantage comes from scale, manufacturing cost, regulatory history, and reliable supply.

How does the market compare with newer antihypertensive drugs?

Factor	Guanethidine monosulfate	Hydrochlorothiazide	ACE inhibitors/ARBs and newer combinations
Clinical role	Historical and limited	Current first-line or add-on use	Broad current use
Patent position	Expired	Expired for core API	Some products have expired; newer products may retain formulation protection
Pricing	Not commercially meaningful	Low generic pricing	Ranges from commodity generic to branded premium
Prescriber demand	Very low	Durable	High
Development activity	Negligible	Limited to combinations	Ongoing for combinations and improved formulations
Substitution risk	Extremely high	Moderate at the therapeutic-class level	Varies by product

Hydrochlorothiazide competes against chlorthalidone, indapamide, loop diuretics, ACE inhibitors, ARBs, calcium-channel blockers, and combination therapies. Some guidelines and clinicians favor chlorthalidone or indapamide in particular settings, creating therapeutic substitution risk, but hydrochlorothiazide retains broad prescribing familiarity.

What generic launch risks exist for these products?

Guanethidine monosulfate

A new entrant would face a small and uncertain market, limited prescriber demand, possible raw-material constraints, and potential difficulty justifying regulatory and manufacturing costs. Patent barriers would be low, but the commercial case would also be weak.

Hydrochlorothiazide

A new generic entrant would face low regulatory and patent barriers but intense price competition. Key risks include:

Low wholesale acquisition price.
Multiple approved suppliers.
Pharmacy benefit manager and wholesaler bargaining power.
Manufacturing concentration.
FDA inspection or quality-system exposure.
Product discontinuation if volumes fall below economic scale.

The strongest opportunity would usually be a supply-constrained market, a differentiated combination product, or a manufacturer with an efficient established antihypertensive platform.

What manufacturing and intellectual-property barriers exist?

Manufacturing hydrochlorothiazide is technically established, and the API does not present a major patent barrier. The commercial barriers are operational:

Consistent API sourcing.
Impurity control.
Content uniformity.
Dissolution performance.
Stable tablet compression and coating.
Bioequivalence documentation.
cGMP compliance.
Reliable packaging and distribution.

Guanethidine may present a different issue: the market is too small to support routine production at many facilities. A manufacturer may face minimum batch sizes, limited API suppliers, and uncertain demand. Those factors can create practical supply barriers even when intellectual-property protection is absent.

What is the financial outlook for guanethidine and hydrochlorothiazide?

Guanethidine monosulfate has no credible growth trajectory in mainstream pharmaceutical markets. Its financial profile is best characterized as legacy, low-volume, and supply-dependent.

Hydrochlorothiazide has a stable but low-margin trajectory:

Prescription demand should remain recurring because hypertension is chronic.
Unit prices should remain under pressure.
Revenue growth is unlikely without a differentiated combination or supply advantage.
Profitability depends on manufacturing scale and portfolio economics.
Market exits may occur when pricing no longer covers compliance and distribution costs.

No reliable public data supports a standalone global revenue estimate for hydrochlorothiazide across all manufacturers. Company filings usually aggregate the drug into broader generic portfolios.

What licensing deals and settlements affect these products?

No major current licensing transaction or settlement is central to the standalone guanethidine monosulfate or hydrochlorothiazide markets. Historical licensing arrangements may exist for branded products or regional distribution, but they do not materially shape current competition.

Settlement risk is more relevant to newer branded antihypertensive combinations with active Orange Book patents. It is not a major factor for conventional hydrochlorothiazide tablets or historical guanethidine products.

Key Takeaways

Guanethidine monosulfate is a legacy antihypertensive with no meaningful current branded market.
Hydrochlorothiazide remains widely used but is a low-price, highly competitive generic.
Core patent protection for both active ingredients expired decades ago.
Standalone hydrochlorothiazide faces low Paragraph IV and patent risk.
Product-specific combination and formulation patents may still require review.
Neither product has biosimilar exposure.
Hydrochlorothiazide revenue is volume-driven and difficult to isolate in public financial filings.
Guanethidine’s principal barriers are weak demand and supply economics, not intellectual property.
Hydrochlorothiazide’s principal risks are price erosion, supplier exits, and manufacturing compliance.

FAQs

Is guanethidine monosulfate still approved in the United States?

Historical FDA approval exists for guanethidine sulfate products, but current commercial marketing availability is limited and should not be equated with historical approval status.[1][2]

Is hydrochlorothiazide a protected drug?

The hydrochlorothiazide molecule and conventional immediate-release tablets are not protected by meaningful current composition patents. Specific combination or formulation products may have separate patent claims.

Can a generic company launch hydrochlorothiazide without a Paragraph IV challenge?

For an unpatented or no-longer-patented conventional product, a Paragraph IV certification may not be necessary. The required ANDA certification depends on the reference product’s current Orange Book listings.[3]

Is guanethidine a viable specialty-generic opportunity?

The opportunity is weak because clinical demand is limited, alternative antihypertensives are widely available, and the market may not support commercial-scale production.

Does hydrochlorothiazide have stronger economics in combination products?

Usually, yes. Combination products can provide greater prescription relevance and portfolio value than standalone hydrochlorothiazide, although pricing remains constrained when multiple generic versions are available.

References

U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. https://www.accessdata.fda.gov/scripts/cder/daf/
National Library of Medicine. (n.d.). DailyMed: Current medication information. https://dailymed.nlm.nih.gov/dailymed/
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
National Library of Medicine. (n.d.). DailyMed drug labels. https://dailymed.nlm.nih.gov/dailymed/

US Patents:	0
Tradenames:	1
Applicants:	1
NDAs:	1
DailyMed Link:	guanethidine monosulfate; hydrochlorothiazide at DailyMed

Guanethidine monosulfate; hydrochlorothiazide - Generic Drug Details

What are the generic sources for guanethidine monosulfate; hydrochlorothiazide and what is the scope of patent protection?

Summary for guanethidine monosulfate; hydrochlorothiazide

Anatomical Therapeutic Chemical (ATC) Classes for guanethidine monosulfate; hydrochlorothiazide

US Patents and Regulatory Information for guanethidine monosulfate; hydrochlorothiazide

Guanethidine Monosulfate and Hydrochlorothiazide: Market Dynamics, Patent Position, and Financial Trajectory